menu
    • menu
    [{"orgOrder":0,"company":"ATPGroup","sponsor":"Intergalactic Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Discovery","graph3":"ATPGroup","amount2":0.080000000000000002,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Ophthalmology","amount2New":0.080000000000000002,"dosageForm":"Ophthalmic Injection","sponsorNew":"ATPGroup \/ ATPGroup","highestDevelopmentStatusID":"2","companyTruncated":"ATPGroup \/ ATPGroup"},{"orgOrder":0,"company":"ATPGroup","sponsor":"Aulos","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"ATPGroup","amount2":0.040000000000000001,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0.040000000000000001,"dosageForm":"Oral","sponsorNew":"ATPGroup \/ ATPGroup","highestDevelopmentStatusID":"4","companyTruncated":"ATPGroup \/ ATPGroup"}]

    Find Clinical Drug Pipeline Developments & Deals by ATPGroup

    Menu

    ATPGroup

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            ATPGroup

                            U.S.A arrow
                            Peptide Process CMC
                            Not Confirmed

                            ATPGroup

                            U.S.A arrow
                            Peptide Process CMC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Recipient : Aulos

                            Deal Size : $40.0 million

                            Deal Type : Series A Financing

                            DEALS_DEV arrow-down

                            ATP and Biolojic Design Launch Aulos Bioscience to Develop Highly Differentiated IL-2 Antibody Approach to Fig...

                            Details : ATP has committed $40 million in Series A funding to advance Aulos' lead molecule from preclinical stage through clinical proof of concept, with human trials expected to start later this year.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            August 01, 2021

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Recipient : Aulos

                            Deal Size : $40.0 million

                            Deal Type : Series A Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            ATPGroup

                            U.S.A arrow
                            Peptide Process CMC
                            Not Confirmed

                            ATPGroup

                            U.S.A arrow
                            Peptide Process CMC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Ophthalmology

                            Study Phase : Discovery

                            Recipient : Intergalactic Therapeutics

                            Deal Size : $75.0 million

                            Deal Type : Series A Financing

                            DEALS_DEV arrow-down

                            ATP Unveils Non-Viral Gene Therapy Innovator Intergalactic Therapeutics with $75 Million in Series A Funding

                            Details : Intergalactic’s non-viral gene therapy deploys two proprietary technologies: 1) C3DNA, covalently closed and circular DNA which relies on a cellfree manufacturing process; and 2) COMET, a clinically advanced, pulsed electric field focal gene therapy d...

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            July 10, 2021

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Discovery

                            Recipient : Intergalactic Therapeutics

                            Deal Size : $75.0 million

                            Deal Type : Series A Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth